Proenkephalin A 119-159 (penKid) Leads the Way in Predicting Graft Outcomes for Kidney Transplant Recipients
PenKid differentiates slow graft function (SGF) from DGF up to 8 days earlier than current methods, supporting more timely clinical decisions.
PenKid levels remain unaffected by kidney replacement therapy (KRT), allowing for more accurate assessment of kidney function.
Independent validation in transplant cohort from Australia confirms performance and broad applicability.
HENNIGSDORF, GERMANY AND BERLIN, GERMANY / ACCESS Newswire / July 1, 2025 / Diagnostic company SphingoTec GmbH ('SphingoTec') announces a landmark study (1) published in Transplant International, led by Heidelberg University Hospital in Germany in collaboration with researchers from Sydney, Australia, which identifies Proenkephalin A 119-159 (penKid) as a reliable biomarker for early and precise assessment of graft function trajectories following kidney transplantation. The research demonstrates that PenKid not only identifies patients at risk for DGF significantly earlier than traditional markers but also distinguishes between slow and delayed graft function with remarkable accuracy, offering clinicians a valuable new tool for patient management.
The study prospectively evaluated 159 consecutive kidney transplant recipients at Heidelberg University Hospital and validated findings in an independent cohort from Sydney. PenKid consistently outperformed serum creatinine (SCr) in predicting graft function trajectories, particularly in the critical early post-transplant period. Notably, PenKid's ability to remain unaffected by KRT-a treatment for severe kidney dysfunction-further sets it apart from SCr, which can be influenced by non-renal factors and KRT itself, thereby enhancing the reliability of graft function assessment.
Multivariate analysis confirmed PenKid as the strongest independent predictor of both short-term graft function and 30-day outcomes, underscoring its clinical utility for early risk stratification. The biomarker's superior granularity allows for nuanced classification of DGF severity, supporting more informed decisions regarding the initiation of dialysis or biopsy and offering potential for individualized patient care.
With these findings, penKid steps forward as a practical addition to the transplant clinician's toolkit, promising to sharpen decision-making for optimal outcomes. Its adoption could help transplant teams act with greater confidence and precision, ultimately strengthening the standard of care in kidney transplantation.
References
Benning L et al. (2025) Proenkephalin A 119-159 in Kidney Transplantation: A Novel Biomarker for Superior Tracking of Graft Function Trajectories. Transpl. Int. 38:14366. doi: 10.3389/ti.2025.14366
About SphingoTec
SphingoTec GmbH ('SphingoTec"; Hennigsdorf near Berlin, Germany) is a biomarker company focusing on the out-licensing of innovative critical care solutions for diagnosing, predicting, and monitoring acute medical conditions. SphingoTec develops its biomarkers to the commercial stage and partners with IVD companies to make them available on different IVD platforms. SphingoTec's proprietary biomarker portfolio includes Proenkephalin A 119-159 (penKid), a biomarker for the assessment of kidney function in critical diseases, commercially available on diagnostic platforms AFIAS and Nexus IB10 and bioactive Adrenomedullin 1-52 (bio-ADM), a biomarker for the assessment of endothelial function in conditions like sepsis. Discover more on www.sphingotec.com
Contact:
Ruxandra Lenz
Marketing and Communication
SphingoTec GmbH
Phone +49-3302-20565-0
Email: [email protected]
SOURCE: SphingoTec GmbH
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Estimating The Intrinsic Value Of Megaport Limited (ASX:MP1)
Key Insights The projected fair value for Megaport is AU$15.13 based on 2 Stage Free Cash Flow to Equity With AU$15.03 share price, Megaport appears to be trading close to its estimated fair value Our fair value estimate is 22% higher than Megaport's analyst price target of AU$12.45 Does the August share price for Megaport Limited (ASX:MP1) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by estimating the company's future cash flows and discounting them to their present value. We will use the Discounted Cash Flow (DCF) model on this occasion. There's really not all that much to it, even though it might appear quite complex. Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you want to learn more about discounted cash flow, the rationale behind this calculation can be read in detail in the Simply Wall St analysis model. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Is Megaport Fairly Valued? We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value: 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Levered FCF (A$, Millions) AU$41.5m AU$52.2m AU$92.0m AU$103.0m AU$124.0m AU$139.9m AU$153.7m AU$165.6m AU$176.1m AU$185.5m Growth Rate Estimate Source Analyst x8 Analyst x7 Analyst x2 Analyst x1 Analyst x1 Est @ 12.81% Est @ 9.85% Est @ 7.78% Est @ 6.33% Est @ 5.32% Present Value (A$, Millions) Discounted @ 8.1% AU$38.3 AU$44.7 AU$72.8 AU$75.3 AU$83.9 AU$87.5 AU$88.9 AU$88.6 AU$87.1 AU$84.8 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = AU$752m We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 8.1%. Terminal Value (TV)= FCF2035 × (1 + g) ÷ (r – g) = AU$185m× (1 + 2.9%) ÷ (8.1%– 2.9%) = AU$3.7b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= AU$3.7b÷ ( 1 + 8.1%)10= AU$1.7b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is AU$2.4b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of AU$15.0, the company appears about fair value at a 0.7% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. The Assumptions We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. You don't have to agree with these inputs, I recommend redoing the calculations yourself and playing with them. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Megaport as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 8.1%, which is based on a levered beta of 1.198. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. See our latest analysis for Megaport SWOT Analysis for Megaport Strength Debt is not viewed as a risk. Weakness Earnings declined over the past year. Opportunity Annual earnings are forecast to grow faster than the Australian market. Current share price is below our estimate of fair value. Threat Revenue is forecast to grow slower than 20% per year. Looking Ahead: Although the valuation of a company is important, it is only one of many factors that you need to assess for a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. For Megaport, we've put together three further factors you should further research: Risks: For instance, we've identified 1 warning sign for Megaport that you should be aware of. Future Earnings: How does MP1's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the ASX every day. If you want to find the calculation for other stocks just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
38 minutes ago
- Yahoo
Commonwealth Bank reveals LMI home loan changes for borrowers
Commonwealth Bank is waiving the cost of lenders mortgage insurance (LMI) for more Australian workers taking out home loans. Banks normally charge LMI if you don't have a 20 per cent deposit, and it currently costs the average buyer around $23,000. The major bank already offers LMI waivers to a range of higher-earning professions, including those in the medical, legal, accounting and finance sectors. For example, some medical professionals like doctors and dentists can borrow up to 95 per cent loan-to-value ratio without paying LMI, while legal professionals like solicitors and barristers can borrow up to 90 per cent LVR without paying the extra cost. From July 30, the major bank introduced new LMI waivers for various professionals, including pharmacists, medical professionals, banking professionals, and judges and magistrates. RELATED Aussie couple reveal 'cheaper' $400,000 housing solution as Commonwealth Bank backs growing trend Centrelink update on little-known support for Aussies in crisis Cash controversy reignites as St George Bank increases fee to deposit or withdraw by 200 per cent Pharmacists now only need to earn $100,000 per annum, down from $150,000, to be eligible for the LMI waiver. Medical professionals with limited registration, such as interns or doctors in supervised practice, will also now be eligible, according to Broker Daily. Judges and magistrates can qualify for waivers using one of several forms of evidence, such as a payslip, tax return or appointment letter. For banking professionals, the major bank has removed the requirement to have salary credits to a CBA account prior to settlement. CBA trialled an extension to their LMI waiver policy to include frontline workers like nurses, police, paramedics and firefighters earlier this year. 'All loans are assessed on a case-by-case basis and adhere to APRA's prudential requirements through robust credit assessments, portfolio monitoring and responsible lending obligations,' a CBA spokesperson told Yahoo Finance. 'We encourage customers to speak with their lender or broker to discuss their personal home loan needs and understand what options are available to them.' Which banks offer LMI waivers? Various banks, including CBA, NAB, Westpac and ANZ, offer LMI waivers for certain professionals, generally those in medicine, law or financial services. Waivers are subject to eligibility criteria depending on the profession, loan type and LVR. Earlier this year, NAB announced it would be expanding its LMI waivers to include more professions, including accountants, lawyers and more medical professionals. Last year, ANZ controversially announced it would allow people living in some of the country's richest areas to borrow up to 95 per cent of a property's value without paying LMI. ANZ included 145 postcodes on the waiver list, including Point Piper, Toorak, Hamilton and Cottesloe. Under the policy, borrowers are required to take out a home loan of $2 million or more and meet income and other requirements to avoid LMI. The federal government has announced plans to allow all Australian first home buyers to purchase with a 5 per cent deposit, avoiding LMI, in an expansion of the existing guarantee scheme. The government would also raise price caps for properties eligible under the scheme, get rid of income caps and the limit on the number of places available. Sydney residents would be able to get in with a new $1.5 million cap, Melbourne $950,000, Brisbane and Canberra $1 million, Adelaide $900,000, Perth $850,000, Hobart $700,000 and Darwin $600,000. This change is set to come into effect from January in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Pleasing Signs As A Number Of Insiders Buy Clara Resources Australia Stock
Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Clara Resources Australia Ltd (ASX:C7A), that sends out a positive message to the company's shareholders. While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. The Last 12 Months Of Insider Transactions At Clara Resources Australia In the last twelve months, the biggest single purchase by an insider was when insider Fred Bart bought AU$175k worth of shares at a price of AU$0.014 per share. So it's clear an insider wanted to buy, even at a higher price than the current share price (being AU$0.004). While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. We always take careful note of the price insiders pay when purchasing shares. As a general rule, we feel more positive about a stock if insiders have bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. Clara Resources Australia insiders may have bought shares in the last year, but they didn't sell any. They paid about AU$0.0091 on average. I'd consider this a positive as it suggests insiders see value at around the current price. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction! View our latest analysis for Clara Resources Australia Clara Resources Australia is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying. Does Clara Resources Australia Boast High Insider Ownership? Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 27% of Clara Resources Australia shares, worth about AU$624k. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders. What Might The Insider Transactions At Clara Resources Australia Tell Us? It doesn't really mean much that no insider has traded Clara Resources Australia shares in the last quarter. However, our analysis of transactions over the last year is heartening. Insiders do have a stake in Clara Resources Australia and their transactions don't cause us concern. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Clara Resources Australia. In terms of investment risks, we've identified 5 warning signs with Clara Resources Australia and understanding these should be part of your investment process. But note: Clara Resources Australia may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
